2018 American Society of Clinical Oncology Annual Meeting*

Pembrolizumab active in the first-line setting for patients with advanced ccRCC with no unexpected toxicities.

This trial met its primary endpoint with an ORR of 40% and showed a manageable and well-tolerated safety profile for erdafitinib in FGFR-altered UC.

Enfortumab vedotin, an investigational antibody-drug conjugate, appears well tolerated in this phase I study with an ORR of 41% in previously treated patients with mUC.

Neoadjuvant therapy with atezolizumab yielded a pCR of 29% in cisplatin-ineligible patients with operable bladder cancer.

Neoadjuvant pembrolizumab associated with a pathologic CR rate of 39.5% and no surgical delay in MIBC patients scheduled for radical cystectomy.

All assessed patient-reported outcomes favored first-line therapy with atezolizumab + bevacizumab over sunitinib in mRCC.

Lenvatinib plus pembrolizumab associated with an ORR of 63% at 24 weeks and tumor size reduction in 29/30 patients.

Combination of a PARP inhibitor plus ADT increases radiologic PFS in patients with docetaxel-treated mCRPC.

In this phase II study, pembrolizumab showed antitumor activity in a subset of previously treated patients with metastatic CRPC regardless of PD-L1 expression status.

Final analysis showed survival with sunitinib alone not inferior to nephrectomy followed by sunitinib.